Kenneth S. Cohen to Brain Stem Neoplasms
This is a "connection" page, showing publications Kenneth S. Cohen has written about Brain Stem Neoplasms.
Connection Strength
2.782
-
Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope? Neuro Oncol. 2017 Aug 01; 19(8):1025-1034.
Score: 0.613
-
A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood. Neuro Oncol. 2013 Jun; 15(6):783-7.
Score: 0.452
-
Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro Oncol. 2011 Apr; 13(4):410-6.
Score: 0.393
-
Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry. Neuro Oncol. 2022 05 04; 24(5):821-833.
Score: 0.213
-
Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol. 2020 06; 21(6):e330-e336.
Score: 0.187
-
Tectal gliomas: natural history of an indolent lesion in pediatric patients. Pediatr Neurosurg. 2000 Jan; 32(1):24-9.
Score: 0.181
-
Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro Oncol. 2018 10 09; 20(11):1547-1555.
Score: 0.167
-
A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study. Pediatr Blood Cancer. 2017 Nov; 64(11).
Score: 0.151
-
Diffusion tensor imaging suggests extrapontine extension of pediatric diffuse intrinsic pontine gliomas. Eur J Radiol. 2016 Apr; 85(4):700-6.
Score: 0.138
-
Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma. Neuro Oncol. 2014 Nov; 16(11):1554-9.
Score: 0.123
-
Treatment of diffuse intrinsic brainstem gliomas: failed approaches and future strategies. J Neurosurg Pediatr. 2009 Apr; 3(4):259-69.
Score: 0.086
-
A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study. Cancer. 2007 Dec 01; 110(11):2535-41.
Score: 0.078